Pharmacokinetics and dosing of arbekacin in preterm and term newborn infants

Pediatrics International

Volumn 45, Issue 2, 2003, Pages 175-179

  Suzuki, Keiji ^a,b   Tanikawa, Kouji ^a   Matsuzaki, Takashi ^a  

^a ST MARIANNA UNIVERSITY   (Japan)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Arbekacin; Low birthweight infant; Newborn; Pharmacokinetics; Preterm infant

Indexed keywords

HABEKACIN;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; GESTATIONAL AGE; HUMAN; INFANT; NEWBORN INFECTION; NEWBORN INTENSIVE CARE; PREMATURITY; PRIORITY JOURNAL;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DIBEKACIN; GENTAMICINS; GESTATIONAL AGE; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE;

EID: 0038583621     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200X.2003.01679.x     Document Type: Article

References (23)

1. Uehara Y, Kikuchi K, Nakamura T et al. Inhibition of methicillin-resistant Staphylococcus aureus colonization of oral cavities in newborns by viridans group streptococci. Clin. Infect. Dis. 2001; 32: 1399-407.
2. Back NA, Linnemann CC Jr, Staneck JL, Kotagal UR. Control of methicillin-resistant Staphylococcus aureus in a neonatal intensive-care unit: use of intensive microbiologic surveillance and mupirocin. Infect. Cont. Hosp. Epidemiol. 1996; 17: 227-31.
3. Karlowicz MG, Buescher ES, Surka AE. Fulminant late-onset sepsis in a neonatal intensive care unit, 1988-1997, and the impact of avoiding empiric vancomycin therapy. Pediatr. 2000; 106: 1387-90.
4. Sung L, Rmotar K, Samson LM, Toye B. Bacteremia due to persistent strains of coagulase-negative staphylococci in a neonatal intensive-care unit. Infect. Cont. Hosp. Epidemiol. 1999; 20: 349-51.
5. Berger A, Salzer HR, Weninger M, Sageder B, Aspock C. Septicaemia in an Austrian neonatal intensive unit: a 7-year analysis. Act. Paediatr. 1998; 87: 1066-9.
6. Fanos V, Dall'Agnola A. Antibiotics in neonatal infections: a review. Drugs 1999; 58: 405-27.
7. Kondo S, Inuma K, Yamamoto K, Maeda K, Umezawa H. Syntheses of 1-N-{(S) -4-amino-2-hydroxybutyryl}-kanamycin B and - 3′,4′-dideoxykanamaycin B active against kanamycin-resistant bacteria. J. Antibiot. 1973; 26: 412-15.
8. Inoue M, Nonoyama M, Okamoto R, Ida T. Antimicrobial activity of arbekacin, a new aminoglycoside antibiotic against methicillin-resistant Staphylococcus aureus. Drugs Exp. Clin. Res. 1994; 20: 233-40.
9. Watanabe T, Ohashi K, Matsui K, Kubota T. Comparative studies of the bactericidal morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 1997; 39: 471-6.
10. Mitomi N, Matsumoto T, Fujigaki M, Komiya I, Kai F. Absorption, distribution, and excretion of arbekacin after intravenous and intramuscular administration in rats [in Japanese]. Japan J. Antibiot. 1987; 40: 357-64.
11. Kurebe M, Yokota M, Niizato T et al. Antibacterial activity and ototoxicity in guinea pigs, and nephrotoxicity in rats, of arbekacin. Arzneimittel-Forschung 1986; 36: 1511-7.
12. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob. Agents Chemother. 1995; 39: 650-5.
13. Fujii R., Sunakawa K, Nishimura T et al. Clinical studies of arbekacin sulfate in the pediatric field [in Japanese]. Japan J. Antibiot. 1994; 47: 57-83.
14. Sakata H, Maruyama S, Ishioka T et al. Pharmacokinetics and influence of arbekacin on renal function in low-birth-weight infants. J. Infect. Chemother. 1997; 3: 160-3.
15. Miranda JC, Schimmel MM, James LS, Spinelli W, Rosen TS. Gentamicin kinetics in the neonate. Ped. Pharmacol. 1985; 5: 57-61.
16. Takimoto M, Yano K, Fujita K, Yoshioka H, Sanae N, Maruyama S. Pharmacokinetics of amikacin in infants and children [in Japanese]. Japan J. Antibiot. 1987; 40: 1125-8.
17. Kildoo CW, Lin LM, Gabriel MH, Folli HL, Modanlou HD. Vancomycin pharmacokinetics in infants: relationship to post-conceptional age and serum creatinine. Dev. Pharmacol. Ther. 1990; 14: 77-83.
18. Totsuka K, Shimizu K, Mitomi N, Niizato T, Araake M. Evaluation of once-daily administration of arbekacin. Experimental study and determination of pharmacokinetic properties in man [in Japanese]. Japan J. Antibiot. 1994; 47: 676-92.
19. Landers S, Berry PL, Kearns GL, Kaplan SL, Rudolph AJ. Gentamicin disposition and effect on development of renal function in the very low birthweight infant. Dev. Pharmacol. Ther 1984; 7: 285-302.
20. Koren G, Leeder S, Harding E, Jacques D, MacLeod SM. Optimization of gentamicin therapy in very low birthweight infants. Ped. Pharmacol. 1985; 5: 79-87.
21. Koren G, James A. Vancomycin dosing in preterm infants: prospective verification of new recommendations. J. Pediatr. 1987; 110: 797-8.
22. Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE. Population pharmacokinetics of vancomycin in neonates. Clin. Pharmacol. Ther. 1994; 56: 169-75.
23. Lundergan FS, Glasscock GF, Kin EH, Cohen RS. Once-daily gentamicin dosing in newborn infant. Pediatr. 1999; 103: 1228-34.